CTOs on the Move

Sight Sciences

www.sightsciences.com

 
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Sight Sciences raised $10M on 10/12/2017
Sight Sciences raised $31M on 09/04/2019
Sight Sciences raised $30M on 03/18/2020
Sight Sciences raised $23.2M on 12/09/2020

Similar Companies

Precision Edge Surgical Products Company

Precision Edge Surgical Products is dedicated to design and manufacture surgical tools and accessories that are second to none in quality while providing exceptional value for our customers.

Specialty Medical Supply

Specialty Medical Supply is a Batavia, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hans Rudolph Inc

Hans Rudolph Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Claret Medical

Claret Medical has been the leader in the field of cerebral protection since 2011, with approximately 97% market share in Europe, and is the first in the category to be commercially available in the U.S.

Neural Analytics

Neural Analytics was created in 2013 when the company`s co-founders were introduced to leading-edge technology in the UCLA Department of Neurology. Leo, Robert and Dan, along with key UCLA faculty and administrators, all saw the potential to commercialize this new technology and build an important company with the potential to help millions of patients around the world.